WO2026057844 - ANTIBODIES TO OX40 AND COMPOSITIONS THEREOF
National phase entry is expected:
Publication Number
WO/2026/057844
Publication Date
19.03.2026
International Application No.
PCT/EP2025/076233
International Filing Date
15.09.2025
Title **
[English]
ANTIBODIES TO OX40 AND COMPOSITIONS THEREOF
[French]
ANTICORPS DIRIGÉS CONTRE OX40 ET COMPOSITIONS LES CONTENANT
Applicants **
LES LABORATOIRES SERVIER
Inventors
DUGUET, Fanny
EL HMOUZI, Jamila
MELANDER, Eva Maria Carlsen
SØNDERGAARD, Elisabeth
Priority Data
24200604.7
16.09.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2739 | |
| EPO | Filing, Examination, Granting | 16672 | |
| Japan | Filing, Examination, Granting | 2615 | |
| South Korea | Filing, Examination, Granting | 2902 | |
| USA | Filing, Examination, Granting | 10140 |
Total:
35,068
Contact Us
Abstract[English]
The present disclosure provides antibodies that bind to OX40, and methods of using them to modulate immunity in a patient in need thereof and to treat autoimmune disorders or immunoinflammatory disorders.[French]
La présente divulgation concerne des anticorps qui se lient à OX40, ainsi que des méthodes pour les utiliser afin de moduler l'immunité chez un patient qui en a besoin et pour traiter des troubles auto-immuns ou des troubles immuno-inflammatoires.